HF
EIGR

HRT Financial’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

HRT Financial’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-971
Closed -$6K – 3323
2023
Q4 		$6K Buy
+971
New +$8.54K ﹤0.01% 2125
2022
Q4 		– Sell
-755
Closed -$170K – 3389
2022
Q3 		$170K Buy
+755
New +$186K ﹤0.01% 2263
2021
Q4 		– Sell
-645
Closed -$129K – 4308
2021
Q3 		$129K Buy
+645
New +$153K ﹤0.01% 2828
2021
Q2 		– Sell
-622
Closed -$165K – 3694
2021
Q1 		$165K Buy
+622
New +$196K ﹤0.01% 2361

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

HRT Financial's EIGR Position: Q1 2024 in Review

HRT Financial sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 971 shares — an estimated $6K sold.

HRT Financial first reported a position in EIGR in Q1 2021 and held it in 4 quarters. The position peaked at $170K in Q3 2022. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • HRT Financial reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • HRT Financial sold 971 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $6K.
  • HRT Financial first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2021 and held it in 4 quarters.
  • HRT Financial's Eiger BioPharmaceuticals, Inc. position peaked at $170K in Q3 2022.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on HRT Financial's 13F filing for Q1 2024, filed 13 May 2024.